Dr. Perez-Soler on Improved Outlook for Patients With Lung Cancer

Video

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the improved outlook for patients with lung cancer.

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the improved outlook for patients with lung cancer.

Twenty years ago, when patients were told that they had lung cancer it meant that they would probably succumb to their disease within a few months. Patients would receive toxic chemotherapy while dealing with symptomatic disease. Today, there are several effective treatment options available, particularly in the stage IV metastatic setting. These new therapies not only provide a physical benefit to patients, but have also helped improve the psychological outlook for patients with the disease. Since there has been so much rapid advancement in the space, the new mentality is that it is worth it to fight the disease; patients know that even more progress is inevitable.

Lung cancer is no longer a disease where oncologists simply don’t know what to do for their patients. There is a renewed interest in conducting research in this space, because investigators are starting to realize that the disease is not as complicated as originally believed. With more science driving research in lung cancer, even more effective therapies could be coming down the pike.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,